

1 **Knockdown AHNAK2 inhibits the progression of**
2 **gastric cancer via the Wnt/ β -catenin signaling pathway**

3 **Xiang Liu^{1†}, Lei Ma^{1†}, Rui-Xiao Wang² and Qi-Lun Liu^{3*}**

4 1.Clinical Medical College of Ningxia Medical University, Yinchuan, Ningxia Hui
5 Autonomous Region 750004, P.R. China

6 2.Department of Pathology, General Hospital of Ningxia Medical University,
7 Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China

8 3.Department of Surgical Oncology, General Hospital of Ningxia Medical University,
9 Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China

10 †These authors contributed equally

11 ***Author for correspondence:** lql631111@163.com

12

13 **ABSTRACT:**

14 **Purpose:**AHNAK2 has been reported as tumor promoting protein by mediating tumor
15 cell invasion and metastasis in a variety of malignancies, but the role of AHNAK2 in
16 GC is indistinct.

17 **Methods:** Immunohistochemistry (IHC) was used to verify in GC tissues, clinical and
18 pathological files were collected to figure out the correlation of AHNAK2 and
19 prognosis in GC patients. GC cell lines were cultured to detect the expression and
20 location of AHNAK2 by westernblot and immunofluorescence. Knockdown
21 AHNAK2 to observe the invasion and metastasis of GC cell. Transcriptome
22 sequencing was performed to explore the potential regulatory mechanism of
23 AHNAK2.

24 **Results:** IHC results shows that AHNAK2 is upregulated in GC patients compared to
25 normal people, overall survival in highly expressed AHNAK2 is poor,and AHNAK2

26 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
expression was positively correlated with lymph node metastasis. The expression of

27 AHNAK2 in tumor cells is higher than in normal cell. Knockdown AHNAK2
28 decreased the proliferation, invasion, migration ability of GC cells, and increased cell
29 apoptosis. Transcriptome sequencing reveals that AHNAK2 mediates GC progression
30 by regulating Wnt/ β -catenin axis.

31 **Conclusion:**Our findings suggest that AHNAK2 may promote the progression of GC
32 by regulating Wnt/ β -catenin signaling pathway.

33 **Keywords:** AHNAK2; Invasion; Metastasis; Progression; Gastric cancer

34 INSTRUCTION

35 Gastric Cancer (GC) has been a significant health concern globally, especially in
36 East Asian countries^[1,2]. In China, the incidence of GC morbidity is significantly high.
37 According to statistics^[3], in 2020, the incidence and mortality of gastric cancer in
38 China accounted for 43.9% and 48.6% of new cases and deaths in the world,
39 respectively.

40 The GC or gastric adenocarcinoma is a highly complex heterogeneous malignant
41 tumor^[4], which significantly limits the application of individualized treatment, thereby
42 resulting in less than 30% of 5-year survival rate in advanced GC patients^[5]. Although
43 targeted therapeutic drugs such as herceptin have been clinically used^[6,7], surgery and
44 perioperative chemotherapy remain the conventional therapy for advanced GC^[8].
45 However, GC patients can acquire chemotherapy resistance, which reduces the
46 therapy's efficiency in inhibiting rapid growth and tumor metastasis^[9]. Therefore,
47 studies on the potential molecular mechanisms of GC are urgently required to inhibit
48 its progression.

49 AHNAK2 is a carcinogenic protein that has been observed to be associated with
50 metastasis of tumors such as clear cell renal cell carcinoma (ccRCC)^[10], pancreatic
51 ductal adenocarcinoma^[11], lung cancer^[12] and thyroid cancer (TC)^[13]. Studies have
52 shown that AHNAK2 is highly expressed in lung adenocarcinoma and is significantly
53 associated with poor prognosis^[14]. Knockout of AHNAK2 significantly reduces
54 scratch healing ability. In addition, mechanism studies suggest that AHNAK2 may be
55 involved in invasion and metastasis of lung adenocarcinoma through the AKT
56 pathway, suggesting that AHNAK2 is involved in the pathogenesis and development
57 of lung adenocarcinoma. However, the biological function of AHNAK2 and its
58 potential regulatory mechanisms in GC remains undetermined.

59 Therefore, this study evaluated the expression and location of AHNAK2 by
60 immunohistochemical analysis of 84 GC patients. Furthermore, the effect of
61 AHNAK2 on prognosis was assessed by analyzing AHNAK2 expression and the
62 patient's clinicopathological features. Moreover, AHNAK2 expression in GC cell
63 lines as well as the malignant biological behaviors of GC while knockdown
64 AHNAK2, such as proliferation, migration, invasion, and apoptosis were assessed.
65 Finally, transcriptome sequencing and further experiments verified the mechanism of
66 AHNAK2's possible involvement in the biological process of GC. This study provides
67 a novel therapeutic approach and foundation for the clinical treatment of GC.

68 **MATERIALS AND METHODS**

69 **Patients Samples and cell culture**

70 This study included 84 radical gastrectomy-diagnosed primary GC patients who
71 were admitted at the Cancer Hospital of Ningxia Medical University General Hospital
72 from January 1, 2017, to December 31, 2017. The Ethics Committee of Ningxia
73 Medical University General Hospital approved this research and the data were
74 analyzed anonymously. All methods were performed in accordance with the relevant
75 guidelines and regulations.

76 The human GC cell lines (AGS, HGC-27, MGC-803, and MKN-45) and
77 corresponding normal gastric epithelial cells (GES-1) were purchased from the
78 Chinese Academy of Medical Sciences (Shanghai, China) and cultured in RPMI-1640
79 medium augmented with FBS (Gibco, USA) and 1% penicillin-streptomycin (Gibco)
80 incubating in 5% CO₂ at 37°C. AHNAK2 expression was detected in all GC cell
81 lines, and the one with the highest expression of AHNAK2 was selected for further
82 experiments.

83 **Data profile collection**

84 The patient's clinicopathological and general data (gender, age, etc.) were
85 retrospectively collected by His system. Furthermore, all the patients were followed
86 up by telephone until December 31, 2022. The follow-up period was 3 - 60 months
87 with a median of 47 months. There were 28 deaths, 25 survivors, and 5 lost to
88 follow-up. The patient's prognosis was expressed by the overall survival time.

89 **Immunohistochemistry**

90 The cancer and adjacent tissues were submerged in paraffin, sliced (4 μm thick),
91 baked, dewaxed, dehydrated, repaired using repair solution for 20 min, cooled down

92 to room temperature, washed with phosphate-buffered saline (PBS), treated with
93 endogenous peroxidase blocker, and then incubated in the dark for 10 min. The
94 samples were then washed with PBS, probed with mono-antibody against AHNAK2
95 (1: 1000; Wuhan Sanying Company) at 4°C overnight, rinsed with PBS, treated with
96 horseradish peroxidase reductase working solution (Zhongshan Jinqiao Company) in
97 the dark for 30 min, and rinsed again with PBS. The samples were then treated with 3,
98 3-diaminobenzidine (DAB) for color development, washed with distilled water,
99 stained in hematoxylin for 5 min, and differentiated using hydrochloric acid alcohol.
100 After washing, the samples were placed in tap water for anti-blue staining, dehydrated,
101 and sealed using transparent neutral resin.

102 **Cell transfection**

103 Sh-AHNAK2 and negative Control (sh-NC) were purchased from Hanheng Biotech
104 Co., LTD (Shanghai, China). MKN45 cells were cultured in the 6-well plate until they
105 reached 80% confluency. The media was then discarded, and Lipofectamine 3000
106 reagent was added for cell transfection. The media was refreshed after 24 h. After 48
107 h, cells with MOI = 30 were observed and selected for follow-up experiments.
108 Transfection efficiency was detected by qRT-PCR and western blot analyses.

109 **Cell immunofluorescence staining**

110 Cell lines with good growth status were cultured, digested, centrifuged,
111 re-suspended, and cultured overnight in pre-treated small discs at appropriate
112 concentrations. The cells were then rinsed with PBS, fixed, blocked, and probed with
113 the primary antibody (1: 40 dilution) at 4°C overnight. The next day, samples were
114 rinsed with PBS buffer, treated with fluorescently labeled secondary antibodies (1:500
115 dilution) at room temperature for 2 h, rinsed again with PBS, and sealed with an
116 anti-fluorescence quencher containing DAPI and blown dry. Based on the fluorescent
117 attached to the secondary antibody, the expression of AHNAK2 was observed and
118 photographed under the microscope through a suitable channel.

119 **Cell Proliferation Assay**

120 Briefly, the transfected cells were cultured in a 6-well plate. When the number of
121 cloned cells exceeded 50, the medium was aspirated, cells were rinsed with PBS
122 thrice, fixed with 4% paraformaldehyde for 15 min at room temperature, washed
123 again with PBS, and stained with 0.5 mL 0.05% crystal violet solution for 20 min.
124 The excess crystal violet dye was cleaned by rinsing with PBS thrice, and cells were
125 air-dried before clone formation rate analysis and imaging via a digital camera.

126 **Cell Migration and Invasion Assay**

127 Cell migration and invasion abilities were evaluated by wound healing and
128 transwell analyses, respectively. For wound healing or migration analysis: the cells
129 were cultured in a 6-well plate at 37°C for 8 h. Upon 80% confluency per well, the
130 cells were then scraped using a pipette tip to create a wound, washed with PBS, and
131 allowed to grow in serum-free media. The wound closure distance was measured
132 under a microscope at 0 and 48 h. For invasion or Transwell analysis: First, the matrix
133 gel was melted and diluted in a serum-free medium at a ratio of 1:6, which was then
134 added to the upper portion of the perforated chamber. In the lower chamber, 500 μ L
135 of serum-free medium was added to rehydrate the basement membrane, whereas in
136 the upper chamber, 1 mL of cell suspension was then added for 24 h. The uninfected
137 cells were discarded, and the remaining cells were washed thrice, fixed with 4%
138 paraformaldehyde, and stained with 0.1% crystal violet. The detection of migration
139 ability was explored in the absence of matrix gels.

140 **Flow Cytometry Assay**

141 The cell apoptosis rate was determined by following the instructions provided in
142 the Cell Apoptosis Detection kit. Briefly, the transfected MKN-45 cells were
143 re-suspended and then treated with 10 μ L Annexin V-fluorescein isothiocyanate
144 (FITC) and 5 μ L propidium iodide (PI) for 15 min at 25°C in the dark. Subsequently,
145 the apoptotic rate was analyzed using a flow cytometer (BD Biosciences, San Jose,
146 CA, USA).

147 **qRT-PCR**

148 The tumor cell RNA was extracted per the instructions of the kit (Invitrogen;
149 Thermo Fisher Scientific, Inc) and then reverse transcribed into cDNA, which was
150 then subjected to qRT-PCR. The amplification conditions were as follows: 95°C for 5
151 min, followed by 40 cycles of 95°C for 30 s, 55°C for 20 s, and 72°C for 20 s. The
152 relative expression of AHNAK2 was analyzed using the $2^{-\Delta\Delta CT}$ method. GAPDH
153 was used as a housekeeping gene. The sequences of primers employed for qRT-PCR
154 are as follows:

155 AHNAK2:

156 Forward: 5' -GACCTGCCTCTTCCCAAACA-3,

157 Reverse: 5' -GCGAGTACTTGGTCATGGCT-3.

158 GAPDH:

159 Forward: 5' -TCAAGGCTGAGAACGGGAAG-3,

160 Reverse: 5' -TCGCCCCACTTGATTTTGGGA -3.

161 **Western Blotting**

162 The cultured cells were treated with 100 μ L protein lysate, scraped, and transferred
163 to the EP tube on ice for 30 min. The cells were then centrifuged at 4°C and at 12000
164 rpm for 15-30 min to collect the supernatant. The acquired proteins in the supernatant
165 were quantified using the BCA method. The proteins (30 μ g) were then subjected to
166 gel electrophoresis, transferred to the membrane, blocked with 5% skim milk for 2 h,
167 rinsed with TBST buffer thrice for 5 min each time, and then treated overnight with
168 polyclonal antibody against rabbit and human AHNAK2 (1: 1000; American OriGene
169 Company) and β -actin (Wuhan Sanying Company) at 4°C. The next day, the
170 membranes were rinsed with TBST buffer, probed with the secondary anti-sheep and
171 anti-rabbit HRP antibodies (Wuhan Sanying Company) for 2 h at room temperature,
172 washed with TBST buffer, and reacted with ECL for protein band development.
173 Image J was used to analyze the gray value of the image and the relative expression
174 level of the AHNAK2 protein. The experiment was repeated three times.

175 **Statistical Analysis**

176 All data were analyzed by SPSS 22.0 and GraphPad Prism 8 and presented as mean
177 \pm standard deviation (SD). The intergroup differences were compared by T-test,
178 whereas the difference between more than 2 groups was compared by one-way
179 analysis of variance. Kaplan-Meier curves were used to estimate the patient's survival
180 rate. $p < 0.05$ indicated that the data had statistically significant differences.

181

182 **RESULT**

183 **AHNAK2 is upregulated in GC tissues**

184 This study performed immunohistochemical staining of samples from 84 GC
185 patients to assess the expression and localization of AHNAK2. The results indicated
186 that 69.0% (58/84) GC patients had high AHNAK2 expression in the tumor tissue,
187 while 31.0% (26/84) GC patients had no AHNAK2 expression, which was also
188 negative in all adjacent normal tissues. Altogether, AHNAK2 was observed to be
189 upregulated in GC tissues (Figure 1A).

190 **Relationship between AHNAK2 and clinicopathological features of GC patients**

191 The 58 AHNAK2-positive patients were categorized into high and low AHNAK2
192 groups based on expression levels acquired by multiplying the staining degree score
193 (percentage of positive cells) with the staining intensity score, with a median of 2 as
194 the limit. There were 32 cases with high AHNAK2 expression and 26 cases with low
195 expression. It was also observed that AHNAK2 expression was positively correlated
196 with lymph node metastasis (LNM) in GC patients ($p<0.05$). Furthermore, AHNAK2
197 was not associated with age, sex, tumor differentiation, pT stage, pathological stage,
198 and the presence of vascular cancer thrombus ($p>0.05$) (Table 1).

199 **Table 1:** Correlation of AHNAK2 expression and clinicopathological features in GC
200 patients

201 The 58 AHNAK2-positive GC patients were followed up till December 31, 2022 (5
202 years postoperatively). During this period, 5 patients were lost to follow-up and 28
203 died, with an overall survival rate of 47.2%. Among these, the 1-, 3-, and 5-year
204 survival rates of high AHNAK2 expression GC patients were 82.1% (23/28), 42.9%
205 (12/28), and 35.7% (10/28), respectively. Whereas the 1-, 3-, and 5-year survival rates
206 of low AHNAK2 expression GC patients were 95.7%(22/23), 69.6%(16/23), and
207 56.5%(13/23), respectively. Overall, these data indicate that high AHNAK2
208 expression patients had a lower survival rate than low AHNAK2 expression patients
209 ($p<0.05$) (Figure 1B).

210 **Figure 1:** AHNAK2 is upregulated in GC and associated with poor prognosis. (A)
211 Expression of AHNAK2 in gastric cancer and adjacent tissues. (B) AHNAK2 is
212 associated with poor prognosis of gastric cancer.

213 **AHNAK2 was up-regulated in GC cell lines**

214 The normal gastric epithelial cells (GES-1) and four GC cell lines (HGC-27, AGS,
215 MGC-803, MKN-45) were selected to analyze their AHNAK2 expression. It was
216 revealed that AHNAK2 expression in all GC cells was higher than in GES-1 cells,
217 with MKN-45 GC cells indicating the highest expression (Figure 2A-D). Therefore,
218 MKN-45 GC cells were selected for subsequent experiments. Furthermore, AHNAK2
219 was observed to be predominantly expressed on the cell membrane. From these
220 results, it was inferred that AHNAK2 was upregulated in GC cells.

221 **AHNAK2 knockdown inhibits MKN-45 cell proliferation**

222 To further study the biological role of the AHNAK2 in GC, MKN-45 cells were
223 utilized to construct stable AHNAK2 knockdown cell lines via lentivirus-mediated
224 gene transfection. qRT-PCR analysis revealed that the knockdown efficiency of
225 mRNA level in shRNA-AHNAK2 cells was 53% (Figure 2E). Furthermore, western
226 blot analysis also confirmed the construction of AHNAK2 knockdown stable
227 transmutation (Figure 2F-G). Cell clonogenesis experiments are used to assess cell
228 proliferation capacity and population dependence to indicate differences in
229 cell-independent viability. The cancer cell's malignant degree increases with the
230 increase in clonogenesis ability. Here, the clonogenesis assay was performed to assess
231 how AHNAK2 downregulation affects the malignant proliferation of GC cells. It was
232 revealed that on the 13th day after shRNA-AHNAK2 transfection, the number of
233 clone cells was significantly reduced compared with that in the shRNA-NC group,
234 indicating that AHNAK2 knockdown could inhibit GC cell proliferation (Figure
235 2H-I).

236 **Figure 2:** AHNAK2 promotes the proliferation of GC cells. (A) Western blot showed
237 the expression of AHNAK2 in different GC cell lines compared with normal cell. (B)
238 Semi-quantitative analysis of AHNAK2 expression in different cells in Fig2A. (C)
239 immunocytofluorescent analysis of AHNAK2 in different cells. Scale=100 μ m. (D)
240 Semi-quantitative analysis of AHNAK2 expression in different cells in Fig2C. (E)
241 Knockdown efficiency of shRNA-AHNAK2 by qRT-PCR.(F) Western blot was used
242 to detect the expression of AHNAK2 in different groups. (G) Semi-quantitative
243 analysis of AHNAK2 expression in different cells in Fig2F. (H) Colony formation
244 assay of GC cells in shRNA-AHNAK2 and shRNA-NC groups.(I) Semi-quantitative
245 analysis of Fig2G. ** $p < 0.05$; *** $p < 0.001$, **** $p < 0.0001$.

246 **AHNAK2 knockdown suppresses MKN-45 cell migration and invasion, as well as** 247 **induces apoptosis**

248 The cell's ability to migrate is the premise of tumor invasion and metastasis. To
249 assess the cell's migration ability, the shRNA-NC and shRNA-AHNAK cells were
250 scratched, cultured, and photographed at 0 and 48 h, and the relative migration area of
251 the cells transferred to the scratch zone under each high-power field of view was
252 calculated after 48 h. Compared with shRNA-NC, the migration ability of the
253 shRNA-AHNAK2 cells was significantly decreased ($p < 0.05$) (Figure 3A-B). The
254 transwell assay was performed to assess the effect of AHNAK2 knockdown on the
255 GC cell's invasion ability. Compared with the control and shRNA-NC cells, the
256 invasion ability of the shRNA-AHNAK2 cells was significantly inhibited. This
257 suggests that AHNAK2 can promote the invasion of GC cells (Figure 3C-D).
258 Furthermore, the flow cytometry analysis revealed that the apoptotic rate of the

259 shRNA-AHNAK2 cells was significantly higher than the MKN-45 and shRNA-NC
260 cells (Figure 3E-F, $p < 0.05$), indicating that AHNAK2 knockdown could promote GC
261 cells apoptosis. Moreover, western blot analysis was performed to assess the levels of
262 anti-apoptotic protein Bcl-2 and pro-apoptotic proteins Bax and Caspase3. It was
263 found that the expression levels of apoptotic proteins were increased after AHNAK2
264 knockdown (Figure 3G-H).

265 **Figure 3.** Effects of AHNAK2 on invasion, migration, and apoptosis of GC cells.(A)
266 Cell migration assay was performed at 0 hour and 48 hour in different groups.(B)
267 Semi-quantitative analysis of Fig3A. (C) Transwell chamber invasion assay was used
268 to detect the invasion ability of cells in different groups. (D) Semi-quantitative
269 analysis of Fig3C.(E) Flow cytometry was used to detect cell apoptosis in different
270 groups.(F) Semi-quantitative analysis of Fig3E.(G) western blot was used to detect
271 the expression of Bcl-2、 Bax and Caspase3 protein expression in MKN-45 cells after
272 knocking down AHNAK2.(H) Semi-quantitative analysis of Fig3G.* $p < 0.05$; *** $p <$
273 0.001 , **** $p < 0.0001$.

274 **AHNAK2 knockdown inhibits the progression of GC cells by suppressing the** 275 **Wnt/ β -catenin signaling pathway**

276 To explore the potential molecular mechanism of AHNAK2 in regulating GC
277 progression, transcriptional sequencing, and bioinformatics analysis were performed
278 on the shRNA-NC and shRNA-AHNAK2 cells, which revealed 790 up-regulated and
279 1389 down-regulated differentially expressed genes (DEGs) between the two groups
280 (Figure 4A). Furthermore, KEGG and GSEA enrichment analysis of these DEGs
281 showed that AHNAK2 might be associated with GC progression via the
282 Wnt/ β -catenin signaling pathway (Figure 4B - C). To investigate whether AHNAK2
283 regulates GC progression by mediating Wnt/ β -catenin, the expression of key
284 Wnt/ β -catenin pathway proteins including Wnt3a, GSK-3 β , p-GSK-3 β , β -catenin,
285 PCNA, cyclinD2, Cdk4, and c-Myc in control, shRNA-NC and shRNA-AHNAK2
286 cells was assessed by Western blot. It was found that AHNAK2 knockdown
287 decreased the expressions of Wnt3a, GSK-3 β , p-GSK-3 β , β -catenin, PCNA, cyclinD2,
288 Cdk4, and c-Myc (Figure 4D-F, $p < 0.05$). Western blot verification results were
289 consistent with the above transcriptome sequencing results, indicating that AHNAK2
290 may play an effect on GC via the Wnt/ β -catenin pathway.

291 **Figure 4.** AHNAK2 promotes the proliferation, migration and invasion of gastric
292 cancer by mediating Wnt/ β -catenin signaling pathway.(A) Differential genes in cell
293 sequencing data from shRNA-NC and shRNA-AHNAK2 groups of GC cell are
294 shown in volcano plots. Red dots indicate up-regulated genes, blue dots indicate

295 down-regulated genes. (B) KEGG enrichment showed the top 20 signaling pathways
296 of differentially expressed genes. (C) GSEA analysis showed that Wnt/ β -catenin
297 signaling pathway was enriched between the two groups. (D) Western blot was used
298 to detect the expression of Wnt3a in different groups.(E) Western blot was used to
299 detect the expression of GSK-3 β , p-GSK-3 β and c-myc in different groups.(F)
300 Western blot was used to detect the expression of β -catenin,PCNA,Cdk4 and
301 cyclinD2 in different groups.(G)Semi-quantitative analysis of Fig4D-E. (H)
302 Semi-quantitative analysis of Fig4F. * $p < 0.05$, ** $p < 0.01$; *** $p < 0.001$.

303

304 DISCUSSION

305 Gastric cancer is an epithelial malignancy with the 4th highest mortality rate among
306 all cancers globally^[3]. Due to its latent early symptoms, most patients are diagnosed at
307 an advanced stage. It has been estimated that the 5-year survival rate of GC patients
308 with distant metastasis is less than 5%^[15]. Currently, the GC treatment mainly includes
309 surgery, radiotherapy, and chemotherapy, which effectively improve the patient's
310 survival rate and quality of life, however, there are still cases of recurrence,
311 metastasis, and drug resistance^[16]. Although several studies have been performed on
312 the etiology and pathophysiology of GC in recent years, the reliable and efficient
313 therapeutic targets are limited.

314 AHNAK2 is a member of the AHNAK family that is located on human
315 chromosome 14q32^[17].It has been indicated that AHNAK2 is crucially
316 associated with the progression of various cancers^[18]. A study analyzed 178
317 pancreatic ductal adenocarcinoma patients and indicated that high
318 expression of AHNAK2 was associated with poor prognosis^[19]. High
319 AHNAK2 expression was also found to be upregulated in lung
320 adenocarcinoma, and its high expression was positively correlated with
321 LNM, severe staging, and poor survival^[20,21]. Another study indicated that
322 AHNAK2 plays a carcinogenic role in ccRCC, and high AHNAK2
323 expression has been linked with late-stage, metastasis, and shorter survival
324 rate^[10]. Furthermore, Koguchi^[22] revealed that AHNAK2 expression was high in
325 bladder cancer, whereas, the normal uroepithelial cells no had no AHNAK2
326 expression. Moreover, their survival analysis indicated that high AHNAK2
327 expression was linked with poor prognosis. In this study, high AHNAK2
328 expression was observed in both GC tissues and cell lines, and it was
329 positively correlated with LNM in GC patients. Furthermore, high AHNAK2
330 expression patients had poor prognosis, suggesting that AHNAK2 may be

331 involved in tumor progression and therefore, AHNAK2 can be utilized as an
332 indicator for poor prognosis in GC patients.

333 Metastasis of cancer cells is a complex biological process, which
334 involving invasion, migration and proliferation^[23]. Those processes not only
335 greatly affect outcomes and survival expectations of patients, but also make
336 treatment strategies tricky. To date, the biological role of AHNAK2 in
337 cancer is relatively consistent. Studies have shown that AHNAK2 expression
338 is up-regulated in TC tissues, especially in metastatic TC tissues, and
339 down-regulation of AHNAK2 can inhibit the migration, invasion and
340 metastasis of TC^[24]. Lin also found that high AHNAK2 expression was closely
341 related to the pathological staging of TC, whereas its knockdown inhibited the
342 proliferation, metastasis, and epithelial-mesenchymal transformation (EMT) of
343 thyroid cancer cells^[25]. EMT is considered to be the premise of cancer growth,
344 invasion and metastasis, and plays an important role in cancer progression and
345 metastasis, EMT can also increase the resistance of cancer cells to chemotherapy and
346 immunotherapy^[26-28]. At the same time, studies have shown that AHNAK2 plays as
347 tumor promoter by promoting epithelial cells which acquire a series of mesenchymal
348 features^[14]. Wang suggested that when AHNAK2 was down-regulated, MAPK/ERK
349 signaling pathway was inhibited, and lung cancer cell migration and invasion abilities
350 were reduced, whereas the apoptosis rate was significantly enhanced^[12]. A study on
351 the regulation of AHNAK2 in uveal melanoma found that reducing the expression of
352 AHNAK2 could inhibit the proliferation, migration and invasion of uveal melanoma
353 cells, and also inhibit the activation of the phosphoinositide 3-kinase(PI3K) signaling
354 pathway^[29]. Similarly, the current study suggests that AHNAK2 plays a tumorigenic
355 role in tumor growth and progression in ccRCC. Knocking down AHNAK2 inhibits
356 tumor proliferation, migration and colony formation in vitro and reduces tumor
357 growth in vivo. In addition, downregulation of AHNAK2 inhibits fatty acid and lipid
358 synthesis, which is an important process for maintaining cancer energy and cellular
359 nutrition, suggesting that the carcinogenic effects of AHNAK2 may be achieved by
360 altering cellular tumor metabolism^[10]. Recent studies have found that AHNAK2 is
361 also highly expressed in various adenocarcinoma tissues, while it is almost not
362 expressed in normal glandular tissues. In vitro experiments found that knocking down
363 AHNAK2 can significantly inhibit the proliferation and migration ability of
364 adenocarcinoma cell lines, proving that AHNAK2 is a biomarker and it can be a
365 potential therapeutic target for adenocarcinoma^[30]. Here, our results demonstrated that
366 knockdown AHNAK2 can alleviate clonogenesis ability, which means malignant
367 growth of GC cells was reduced. And at the same time, suppressing AHNAK2 can
368 reduce the ability of migration and invasion of GC cells. while the apoptosis rate

369 increased. Altogether, these results indicated that inhibiting AHNAK2 might
370 suppressed the progression of GC. This further confirms that AHNAK2 is involved in
371 GC progression and plays an important biological role.

372 In the early stage of this study, it was found that AHNAK2 can promote GC
373 progression. In order to further explore its potential regulatory mechanism,
374 transcriptomic sequencing was performed. The enrichment analysis results suggested
375 that the significant difference pathway was Wnt signaling pathway. Wnt signaling
376 pathway is one of the main pathways involved in human embryo and organ
377 development, it has been related to various biological processes of tumor cells, such
378 as proliferation, migration, differentiation, and apoptosis^[31]. The activation of Wnt
379 signaling pathway is mainly divided into classical Wnt/ β -catenin signaling pathway,
380 Wnt/ Ca^{2+} pathway and Wnt/PCP pathway^[32]. Once the Wnt/ β -catenin signaling
381 pathway activated, the core protein molecule β -catenin is transferred from the
382 cytoplasm to the nucleus, thus promoting the expression of related target genes such
383 as cell proliferation, differentiation and migration^[33]. More and more studies have
384 confirmed that the Wnt signaling pathway plays an irreplaceable role in the
385 development and progression of GC^[34-36]. It has been estimated that 46% of gastric
386 tumors have dysregulated Wnt/ β -catenin pathway^[37]. A study analyzed 13 GC cell
387 lines and revealed nuclear localization of endogenous β -catenin and increased
388 TCF/LEF transcriptional activity, confirming abnormal Wnt signaling^[38]. The KEGG
389 pathway analysis has revealed that the Wnt pathway is the 3rd active pathway in GC,
390 and its downstream factors RNF43, AXIN1/2, CTNNB1, and APC are frequently
391 mutated^[39]. In our study, we found that the expression of related proteins of Wnt
392 pathway was decreased while knockdown AHNAK2, suggesting that AHNAK2 may
393 regulate GC progression via the Wnt/ β -catenin pathway.

394 In summary, this study indicates that AHNAK2 participates in the regulation of
395 malignant biological behaviors such as proliferation, apoptosis, migration and
396 invasion of gastric cancer cells, and it may achieved by the activation of
397 Wnt/ β -catenin signal, revealing that AHNAK2 can be used as a potential therapeutic
398 target for the treatment of gastric cancer. It provides a new theoretical mechanism and
399 support for the treatment of gastric cancer.

400 CONCLUSION

401 In summary, this study revealed that the AHNAK2 protein can serve as a
402 biomarker to indicate poor prognosis in GC patients and a novel molecular
403 target for diagnosis and treatment of this malignancy.

404 **Acknowledgments**

405 The RNA libraries were sequenced by OE Biotech, Inc, Shanghai, China. We are
406 grateful to OE Biotech, Inc, (Shanghai, China) for assisting in sequencing and/or
407 bioinformatics analysis. All colleagues involved in this study for their contributions.

408 **Funding**

409 This work is supported by grants from the National Natural Science Foundation of
410 China (82060663), and the Natural Science Foundation of Ningxia (2020BEG03031).

411 **Data availability**

412 Datasets generated and/or analyzed during the current study are available at the
413 National Center for Biotechnology Information in the repository,
414 [[https://dataview.ncbi.nlm.nih.gov/object/PRJNA1214896?reviewer=o3idag4aqm507](https://dataview.ncbi.nlm.nih.gov/object/PRJNA1214896?reviewer=o3idag4aqm507rh0obobeaei4r)
415 [rh0obobeaei4r](https://dataview.ncbi.nlm.nih.gov/object/PRJNA1214896?reviewer=o3idag4aqm507rh0obobeaei4r)] ". All data and materials are available in the paper and the
416 supplementary information. Source data are provided with this paper.

417 **Authors' contributions**

418 Q-L L and XL designed the study and confirmed the authenticity of all the raw data.
419 XL and LM performed data analysis and drafted the manuscript. XL and LM
420 performed verification experiments and improved the language of the manuscript.
421 R-X W contributed to technical support and histological evaluation. All authors have
422 read and approved the final manuscript.

423 **Ethics approval and consent to participate**

424 The study on human tissues was approved by the Ethics Committee of Ningxia
425 Medical University General Hospital (ethics code: KYLL-2024-0023).

426 **Patient consent for publication**

427 Not applicable

428 **Competing interests**

429 The authors declare no competing interests.

430

431 **REFERENCE**

432


- 433 [1] L-A Torre, Siegel R-L, Ward E-M, et al. Global Cancer Incidence and Mortality
434 Rates and Trends--An Update[J]. *Cancer Epidemiol Biomarkers Prev*, 2016, 25(1):
435 16-27.
- 436 [2] The global, regional, and national burden of stomach cancer in 195 countries,
437 1990-2017: a systematic analysis for the Global Burden of Disease study 2017[J].
438 *Lancet Gastroenterol Hepatol*, 2020, 5(1): 42-54.
- 439 [3] H Sung, Ferlay J, Siegel R-L, et al. Global Cancer Statistics 2020: GLOBOCAN
440 Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
441 Countries[J]. *CA Cancer J Clin*, 2021, 71(3): 209-249.
- 442 [4] N-Y Chia, Tan P. Molecular classification of gastric cancer[J]. *Ann Oncol*, 2016,
443 27(5): 763-769.
- 444 [5] V-E Strong. Progress in gastric cancer[J]. *Updates Surg*, 2018, 70(2): 157-159.
- 445 [6] M Sanford. Trastuzumab: a review of its use in HER2-positive advanced gastric
446 cancer[J]. *Drugs*, 2013, 73(14): 1605-1615.
- 447 [7] C Gomez-Martin, Lopez-Rios F, Aparicio J, et al. A critical review of
448 HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and
449 beyond[J]. *Cancer Lett*, 2014, 351(1): 30-40.
- 450 [8] W Xu, Yang Z, Lu N. Molecular targeted therapy for the treatment of gastric
451 cancer[J]. *J Exp Clin Cancer Res*, 2016, 351.
- 452 [9] S Russi, Verma H-K, Laurino S, et al. Adapting and Surviving: Intra and
453 Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells[J]. *Int J Mol*
454 *Sci*, 2019, 20(15).
- 455 [10] M Wang, Li X, Zhang J, et al. AHNAK2 is a Novel Prognostic Marker and
456 Oncogenic Protein for Clear Cell Renal Cell Carcinoma[J]. *Theranostics*, 2017,
457 7(5): 1100-1113.
- 458 [11] D Lu, Wang J, Shi X, et al. AHNAK2 is a potential prognostic biomarker in
459 patients with PDAC[J]. *Oncotarget*, 2017, 8(19): 31775-31784.
- 460 [12] D-W Wang, Zheng H-Z, Cha N, et al. Down-Regulation of AHNAK2 Inhibits Cell
461 Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway
462 in Lung Adenocarcinoma[J]. *Technol Cancer Res Treat*, 2020, 191079224654.

- 463 [13]Z Xie, Lun Y, Li X, et al. Bioinformatics analysis of the clinical value and potential
464 mechanisms of AHNAK2 in papillary thyroid carcinoma[J]. Aging (Albany NY),
465 2020, 12(18): 18163-18180.
- 466 [14]S Zhang, Lu Y, Qi L, et al. AHNAK2 Is Associated with Poor Prognosis and Cell
467 Migration in Lung Adenocarcinoma[J]. Biomed Res Int, 2020, 20208571932.
- 468 [15]A-P Thrift, El-Serag H-B. Burden of Gastric Cancer[J]. Clin Gastroenterol
469 Hepatol, 2020, 18(3): 534-542.
- 470 [16]E-C Smyth, Nilsson M, Grabsch H-I, et al. Gastric cancer[J]. Lancet, 2020,
471 396(10251): 635-648.
- 472 [17]A Komuro, Masuda Y, Kobayashi K, et al. The AHNAKs are a class of giant
473 propeller-like proteins that associate with calcium channel proteins of
474 cardiomyocytes and other cells[J]. Proc Natl Acad Sci U S A, 2004, 101(12):
475 4053-4058.
- 476 [18]M Zardab, Stasinou K, Grose R-P, et al. The Obscure Potential of AHNAK2[J].
477 Cancers (Basel), 2022, 14(3).
- 478 [19]H Klett, Fuellgraf H, Levit-Zerdoun E, et al. Identification and Validation of a
479 Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal
480 Adenocarcinoma[J]. Front Genet, 2018, 9108.
- 481 [20]G Liu, Guo Z, Zhang Q, et al. AHNAK2 Promotes Migration, Invasion, and
482 Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the
483 TGF-beta/Smad3 Pathway[J]. Onco Targets Ther, 2020, 1312893-12903.
- 484 [21]M Zheng, Liu J, Bian T, et al. Correlation between prognostic indicator AHNAK2
485 and immune infiltrates in lung adenocarcinoma[J]. Int Immunopharmacol, 2021,
486 90107134.
- 487 [22]D Koguchi, Matsumoto K, Shimizu Y, et al. Prognostic Impact of AHNAK2
488 Expression in Patients Treated with Radical Cystectomy[J]. Cancers (Basel),
489 2021, 13(8).
- 490 [23]S Gerstberger, Jiang Q, Ganesh K. Metastasis[J]. Cell, 2023, 186(8): 1564-1579.
- 491 [24]R Ye, Liu D, Guan H, et al. AHNAK2 promotes thyroid carcinoma progression by
492 activating the NF-kappaB pathway[J]. Life Sci, 2021, 286120032.


- 493 [25] Q-Y Lin, Qi Q-L, Hou S, et al. Silencing of AHNAK2 restricts thyroid carcinoma
494 progression by inhibiting the Wnt/beta-catenin pathway[J]. *Neoplasma*, 2021,
495 68(5): 1063-1071.
- 496 [26] Y Huang, Hong W, Wei X. The molecular mechanisms and therapeutic strategies
497 of EMT in tumor progression and metastasis[J]. *J Hematol Oncol*, 2022, 15(1):
498 129.
- 499 [27] Y Cai, Wang B, Li B, et al. Collection on reports of molecules linked to
500 epithelial-mesenchymal transition in the process of treating metastasizing cancer:
501 a narrative review[J]. *Ann Transl Med*, 2021, 9(11): 946.
- 502 [28] A Dongre, Weinberg R-A. New insights into the mechanisms of
503 epithelial-mesenchymal transition and implications for cancer[J]. *Nat Rev Mol*
504 *Cell Biol*, 2019, 20(2): 69-84.
- 505 [29] M Li, Liu Y, Meng Y, et al. AHNAK Nucleoprotein 2 Performs a Promoting Role
506 in the Proliferation and Migration of Uveal Melanoma Cells[J]. *Cancer Biother*
507 *Radiopharm*, 2019, 34(10): 626-633.
- 508 [30] M Xu, Cheng A, Yu L, et al. AHNAK2 is a biomarker and a potential therapeutic
509 target of adenocarcinomas[J]. *Acta Biochim Biophys Sin (Shanghai)*, 2022,
510 54(11): 1708-1719.
- 511 [31] J Liu, Xiao Q, Xiao J, et al. Wnt/beta-catenin signalling: function, biological
512 mechanisms, and therapeutic opportunities[J]. *Signal Transduct Target Ther*,
513 2022, 7(1): 3.
- 514 [32] C Niehrs. The complex world of WNT receptor signalling[J]. *Nat Rev Mol Cell*
515 *Biol*, 2012, 13(12): 767-779.
- 516 [33] C-M Cruciat, Niehrs C. Secreted and transmembrane wnt inhibitors and
517 activators[J]. *Cold Spring Harb Perspect Biol*, 2013, 5(3): a15081.
- 518 [34] S Koushyar, Powell A-G, Vincan E, et al. Targeting Wnt Signaling for the
519 Treatment of Gastric Cancer[J]. *Int J Mol Sci*, 2020, 21(11).
- 520 [35] Y Kim, Bae Y-J, Kim J-H, et al. Wnt/beta-catenin pathway is a key signaling
521 pathway to trastuzumab resistance in gastric cancer cells[J]. *BMC Cancer*, 2023,
522 23(1): 922.

- 523 [36]R Han, Yang J, Zhu Y, et al. Wnt signaling in gastric cancer: current progress and
524 future prospects[J]. *Front Oncol*, 2024, 14:1410513.
- 525 [37]C-H Ooi, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical
526 prognosis in gastric cancer[J]. *PLoS Genet*, 2009, 5(10): e1000676.
- 527 [38]M Nojima, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of SFRP
528 genes and constitutive activation of Wnt signaling in gastric cancer[J]. *Oncogene*,
529 2007, 26(32): 4699-4713.
- 530 [39]K Wang, Yuen S-T, Xu J, et al. Whole-genome sequencing and comprehensive
531 molecular profiling identify new driver mutations in gastric cancer[J]. *Nat Genet*,
532 2014, 46(6): 573-582.

533



B
medRxiv preprint doi: <https://doi.org/10.1101/2025.05.29.25328610>; this version posted June 2, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






Figure2




Figure3

Characteristic	Total	AHNAK2 expression		P value
		Low	high	
Gender		26	32	0.431
male	44	21	23	
female	14	5	9	
Age(years)				0.771
<60	30	14	16	
≥60	18	12	16	
Differentiation				0.329
Well	8	4	4	
Moderate	24	10	14	
poor	26	12	14	
pT stage				0.051
T1	3	3	0	
T2	10	7	3	
T3	11	4	7	
T4	34	12	22	
pN stage				0.032
N0	10	8	2	
N1+N2+N3	48	18	30	
TNM Stage				0.258
I - II	20	11	9	
III-IV	38	15	23	
Vascular invasion				0.272
Absent	33	19	14	
Present	17	7	10	

medRxiv preprint doi: <https://doi.org/10.1101/2025.05.29.25328610>; this version posted June 2, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

medRxiv preprint doi: <https://doi.org/10.1101/2025.05.29.25328610>; this version posted June 2, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

